LRMR - NASDAQ

Larimar Therapeutics, Inc.

LRMR·NASDAQ

$3.29

-0.30%

HealthcareBiotechnology

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$281.55M

EPS-2.2700

P/E Ratio-1.45

Earnings Date08/06/2026

lrmr

Accumulated Other Comprehensive Income (Loss)

Last Annual Value

54.00K

3-Year CAGR

55%

5-Year CAGR

122%

10-Year CAGR

Adjust for Inflation

Larimar Therapeutics, Inc. Competitors Analysis of Accumulated Other Comprehensive Income (Loss)

LRMR · NASDAQ

Company	Accumulated Other Comprehensive Income (Loss)	CAGR 3Y	CAGR 5Y	CAGR 10Y
Larimar Therapeutics, Inc. NASDAQ:LRMR	54.00K	-12.6%	N/A	N/A
Alector, Inc. NASDAQ:ALEC	166.00K	-3.4%	N/A	N/A
Editas Medicine, Inc. NASDAQ:EDIT	0.00	N/A	N/A	N/A
LB Pharmaceuticals Inc Common Stock NASDAQ:LBRX	168.00K	-15.0%	N/A	N/A
Lyell Immunopharma, Inc. NASDAQ:LYEL	242.00K	N/A	N/A	N/A
Tenaya Therapeutics, Inc. NASDAQ:TNYA	0.00	N/A	N/A	N/A
Voyager Therapeutics, Inc. NASDAQ:VYGR	32.00K	N/A	N/A	N/A
Replimune Group, Inc. NASDAQ:REPL	5.45M	-1.7%	N/A	N/A
Kyverna Therapeutics, Inc. NASDAQ:KYTX	97.00K	189.4%	N/A	N/A
Korro Bio, Inc. NASDAQ:KRRO	212.00K	N/A	N/A	N/A
Lexeo Therapeutics, Inc. Common Stock NASDAQ:LXEO	188.00K	N/A	N/A	N/A

Larimar Therapeutics, Inc. Fair Value Envelope

LRMR · NASDAQ

Our analysis suggests that LRMR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.29, this represents a potential HIDDEN relative to our calculated worth for Larimar Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $3.29

Related Guides

Blog Categories

Continue your LRMR research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.